<DOC>
	<DOC>NCT01406015</DOC>
	<brief_summary>The purpose of this study is to find out if spironolactone, a drug that blocks the action of aldosterone, can make the blood vessels work better in people with obesity. The investigators also want to find out whether spironolactone causes changes in levels of insulin and markers of inflammation.</brief_summary>
	<brief_title>Mineralocorticoid Receptor and Obesity Induced Cardiovascular Complications</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>1. Age 1870 years 2. Good health as evidenced by history and physical exam 3. BMI: &gt;30 kg/m2 and &lt;45 kg/m2 Exclusion criteria: 1. Medical illnesses other than treated hypothyroidism 2. BP &gt;135/85 or systolic BP &lt;90 mm Hg 3. Hepatic disease (transaminase &gt; 3 times normal) 4. Renal impairment (Creatinine clearance &lt;60 ml/min) 5. Baseline serum K &gt;5.0 mmol/L 6. History of drug or alcohol abuse 7. Allergies to spironolactone 8. Participation in any other concurrent clinical trial 9. Women using oral contraceptives within the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Mineralocorticoid receptor</keyword>
</DOC>